Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.54 |
| ▸ | BRD2 | P25440 | 5/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314133 | 0.76 | SLC6A4 (0.66) | — | |
| SCHEMBL27314227 | 0.74 | BRD4 (0.58) | BRD4BRD2CREBBPBRD3ERN1 | |
| SCHEMBL2554975 | 0.73 | BRD4 (0.54) | BRD4BRD2CREBBPBRD3ERN1 | |
| SCHEMBL27314226 | 0.72 | BRD4 (0.80) | BRD4BRD2CREBBPBRD3ERN1 | |
| SCHEMBL15782904 | 0.72 | BRD4 (0.62) | BRD4BRD2CREBBPBRD3ERN1 | |
| SCHEMBL15070349 | 0.72 | BRD4 (0.75) | BRD4BRD2CREBBPBRD3ERN1 | |
| SCHEMBL2175064 | 0.72 | BRD4 (0.49) | BRD4BRD2BRD3ERN1 | |
| SCHEMBL31735610 | 0.70 | BRD4 (1.00) | BRD4BRD2CREBBPBRD3ERN1 | |
| SCHEMBL16059774 | 0.70 | BRD4 (1.00) | BRD4BRD2CREBBPBRD3ERN1 | |
| SCHEMBL23555362 | 0.70 | CA2 (0.64) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | BRD4 1000/4885BRD2 1144/4885DYRK1A 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.